Introduction
============

Aging is associated with a progressive reduction in muscle mass and strength ([@b1-ijmm-41-03-1245],[@b2-ijmm-41-03-1245]), which is known as sarcopenia. Sarcopenia is recognized as an important risk factor associated with disability and mortality ([@b3-ijmm-41-03-1245]). Daily life is largely affected by the loss of skeletal muscle mass, which subsequently leads to skeletal muscle atrophy ([@b4-ijmm-41-03-1245]). Muscle atrophy is mainly caused by musculoskeletal injury, denervation, ligament and joint immobilization, joint inflammation, joint injuries, prolonged bed rest, sepsis, aging, cancer and gluco-corticoid treatment ([@b5-ijmm-41-03-1245]--[@b7-ijmm-41-03-1245]).

In research, various model organisms of skeletal muscle atrophy have been developed, via unloading ([@b8-ijmm-41-03-1245],[@b9-ijmm-41-03-1245]), immobilization ([@b10-ijmm-41-03-1245]), starvation ([@b11-ijmm-41-03-1245]), denervation ([@b12-ijmm-41-03-1245]) and administration of glucocorticoids ([@b13-ijmm-41-03-1245]). Among them, high doses of dexamethasone (DEXA) stimulate muscle proteolysis causing catabolic alterations in skeletal muscles ([@b14-ijmm-41-03-1245],[@b15-ijmm-41-03-1245]). The ubiquitin-proteasome and lysosomal pathways are predominantly responsible for activation of glucocorticoid-induced protein degradation ([@b16-ijmm-41-03-1245]). Proteins involved in these pathways include atrogin-1, muscle-specific E3-ligases, muscle RING-finger protein-1 (MuRF1), cathepsin L and lysosomal enzyme ([@b17-ijmm-41-03-1245]--[@b19-ijmm-41-03-1245]). Furthermore, upregulation of myostatin is an important negative regulator of skeletal muscle mass ([@b20-ijmm-41-03-1245]), which is associated with glucocorticoid-induced catabolic muscle atrophy ([@b21-ijmm-41-03-1245]). Muscle structure and mass are determined by the equilibrium between protein synthesis and degradation, and various proteins are involved in disused muscle atrophy ([@b9-ijmm-41-03-1245]). The mRNA expression levels of these proteins can be readily detected using reverse transcription polymerase chain reaction (RT-PCR), and RT-quantitative (q) PCR has been used to determine the efficacy of animal models of disused muscle atrophy ([@b9-ijmm-41-03-1245],[@b22-ijmm-41-03-1245]). In addition, apoptosis ([@b23-ijmm-41-03-1245]), muscle fiber loss and destruction of the muscle antioxidant defense system ([@b24-ijmm-41-03-1245],[@b25-ijmm-41-03-1245]) are involved in glucocorticoid-induced catabolic muscle atrophy ([@b26-ijmm-41-03-1245]). These findings suggest that glucocorticoid-induced muscle atrophy is a valuable and efficient animal model that may be used to identify agents that protect against abnormal catabolic muscle atrophy ([@b26-ijmm-41-03-1245]--[@b29-ijmm-41-03-1245]).

Oxymetholone (17β-hydroxy-2-hydroxymethylidene-17 α-methyl-3-androstanone) is an orally active 17α-alkylated anabolic-androgenic steroid ([@b30-ijmm-41-03-1245]). It has a fully saturated cyclic hydrocarbon structure, which may limit the risk of hepato-toxicity ([@b31-ijmm-41-03-1245]). Oxymetholone exhibits higher anabolic activity and lower androgenic activity than methyltestosterone, testosterone and testosterone propionate ([@b32-ijmm-41-03-1245]). Oxymetholone has been approved by the US Food and Drug Administration for the treatment of anemia-associated problems that are caused by deficient red blood cell production ([@b33-ijmm-41-03-1245]). To date, oxymetholone has been used to treat various musculoskeletal disorders and as a reference drug for the production of muscle enhancers ([@b26-ijmm-41-03-1245],[@b33-ijmm-41-03-1245]--[@b35-ijmm-41-03-1245]). However, it also exerts hepatotoxic effects ([@b36-ijmm-41-03-1245],[@b37-ijmm-41-03-1245]) and decreases anticoagulant tolerance ([@b38-ijmm-41-03-1245]).

Numerous polysaccharides are able to activate cellular components involved in host defense mechanisms ([@b39-ijmm-41-03-1245]). β-1,3/1,6-glucan is derived from yeast cell walls and modulates numerous *in vivo* and *in vitro* activities ([@b40-ijmm-41-03-1245]). It has previously been associated with antitumor effects ([@b41-ijmm-41-03-1245]), radioprotective actions ([@b42-ijmm-41-03-1245]), increased host resistance to bacterial, viral and parasitic infections ([@b43-ijmm-41-03-1245]), and adjuvant effects ([@b44-ijmm-41-03-1245]). Extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001 (Polycan) (EAP) contain 13% β-1,3/1,6-glucan ([@b45-ijmm-41-03-1245],[@b46-ijmm-41-03-1245]) as a specific component, and have exhibited favorable antiosteoporotic activities ([@b46-ijmm-41-03-1245]), anti-inflammatory activities against xylene-induced acute ([@b47-ijmm-41-03-1245]) and formalin-induced chronic ([@b48-ijmm-41-03-1245]) inflammation, potent immunomodulatory activities in cyclophosphamide-induced immunosuppressed mice ([@b45-ijmm-41-03-1245]), nephroprotective effects ([@b49-ijmm-41-03-1245]), ameliorating effects on ovalbumin-induced asthma ([@b50-ijmm-41-03-1245]), antiosteoarthritic effects ([@b51-ijmm-41-03-1245]), and therapeutic effects against experimental periodontitis and associated alveolar bone losses ([@b52-ijmm-41-03-1245]), via powerful immunomodulatory, antioxidant and anti-inflammatory mechanisms.

The present study aimed to investigate whether administration of EAP prevented or improved glucocorticoid-induced catabolic muscle atrophy and to examine its possible mechanism(s) of action. EAP (100, 200 and 400 mg/kg) was administered orally, once per day for 24 days; EAP treatment was initiated 2 weeks prior to DEXA treatment in mice. The results from the EAP-treated mice were then compared with those from mice treated with the 17α-alkylated anabolic-androgenic steroid, oxymetholone, at an oral dose of 50 mg/kg ([@b51-ijmm-41-03-1245],[@b52-ijmm-41-03-1245]).

Materials and methods
=====================

Test substances
---------------

Light brown EAP powder was supplied by Glucan Corporation (Busan, South Korea) and was stored at 4°C. EAP consisted of 13% β-1, 3/1,6-glucan and 40% β-glucans, as determined using previously described analytical methods ([@b45-ijmm-41-03-1245],[@b46-ijmm-41-03-1245],[@b53-ijmm-41-03-1245]). Oxymetholone (50 mg tablet; Celltrion, Incheon, South Korea) was used as a reference drug; tablets were ground and were also stored at 4°C protected from light. Ground 50 mg oxymetholone tablets were dissolved at a 15 mg/ml concentration (5 mg/ml oxymetholone) in deionized distilled water. EAP was dissolved at 40 mg/ml in deionized distilled water.

Animals and experimental design
-------------------------------

A total of 60 adult male SPF/ICR mice (6 weeks old), weighing 27--30 g were obtained from orient Bio, Inc. (Seongnam, South Korea). After 10 days of acclimatization, the 48 mice that were well acclimatized in the laboratory environment (8 mice per group; a total of 6 groups) were used in the present study. The mice were maintained in polycarbonate cages (n=4--5 mice/cage) in a humidity (40--45%)- and temperature (20--25°C)-controlled room under a 12-h light/dark cycle. Normal rodent pellets (cat. no. 38057; Purina Feed, Seongnam, South Korea) and water were provided *ad libitum* during acclimation.

Three doses of EAP (100, 200 and 400 mg/kg) were administered orally in a volume of 10 ml/kg, once a day for 24 days; EAP treatment was initiated 2 weeks prior to DEXA treatment. In addition, 50 mg/kg oxymetholone was administered orally, in a similar manner to EAP. EAP was dissolved at 10, 20 or 40 mg/ml in distilled water, and was administered orally in a volume of 10 ml/kg body weight using a zonde needle attached to a 1 ml syringe. Ground 50 mg oxymetholone tablets were also dissolved in distilled water at 15 mg/ml (5 mg/ml as oxymetholone) and administered orally at 10 ml/kg, which was equivalent to 150 mg/kg (50 mg/kg as oxymetholone). The dosage of oxymetholone was selected based on previous efficacy tests in mice ([@b26-ijmm-41-03-1245],[@b33-ijmm-41-03-1245]--[@b35-ijmm-41-03-1245]). Doses of 100, 200 and 400 mg/kg EAP were selected based on previously reported *in vivo* efficacy tests of EAP ([@b45-ijmm-41-03-1245],[@b46-ijmm-41-03-1245]). In the present study, catabolic muscle atrophy was initiated by subcutaneous treatment with 1 mg/kg DEXA, once a day for 10 days, according to previously reported methods ([@b16-ijmm-41-03-1245],[@b26-ijmm-41-03-1245]). Water-soluble DEXA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was dissolved in saline at 1.5 mg/ml (0.1 mg/ml DEXA) and was subcutaneously injected into the cervical dorsal region in a volume of 10 ml/kg, equivalent to 15 mg/kg (1 mg/kg as DEXA itself). An equal volume of deionized distilled water, instead of oxymetholone or EAP, was orally administered in the DEXA control and intact vehicle groups, and an equal volume of saline, instead of DEXA, was injected subcutaneously into the intact vehicle control group. The present study was conducted in accordance with international regulations of the usage and welfare of laboratory animals, and was approved by the Institutional Animal Care and use Committee, Daegu Haany University (Gyeongsan, South Korea; approval no. DHU2016-051, May 27, 2016).

Body weight measurements
------------------------

Body weight (g) was measured 1 day prior to, the day of, and 1, 7, 14, 19, 23 and 24 days after treatment administration using an electronic balance (Precisa Gravimetrics AG, Dietikon, Switzerland). The gain in body weight during the 14 days of pretreatment, the 10 days of DEXA treatment and the total 24-day treatment periods was measured to decrease individual differences, according to equation 1, where BW indicates body weight: During 14 days of pretreatment= BW at 14 days after initial administration - BW at first administration (Eq. 1a).During 10 days of DEXA treatment = BW on the last day of DEXA treatment - BW on the first day of DEXA treatment^a^ (Eq. 1b). ^a^A total of 2 weeks after pretreatment.During total 24 days of treatment = BW at sacrifice - BW on the first day of pretreatment (Eq. 1c).

Calf and gastrocnemius muscle thickness measurements
----------------------------------------------------

The thickness of the left hind calf was measured 1 day prior to, the day of, and 1, 7, 14, 19, 23 and 24 days after treatment administration using electronic digital calipers (Mitutoyo, Tokyo, Japan), similar to previous studies ([@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245]). Gastrocnemius muscle thickness in the left hind limb was measured following muscle exposure after sacrifice (all mice were sacrificed at the end of the 24-day period; liver, kidney, pancreas, calf muscle mass and gastrocnemius muscle tissues were collected following sacrifice), in order to decrease variability from the surrounding tissues. Gastrocnemius muscle thickness was measured according to the method used to measure calf thickness; alterations in calf thickness (mm) during 14 days of pretreatment, 10 days of DEXA treatment and the total 24-day treatment period were measured to reduce individual differences, according to equation 2, where CT indicates calf thickness: During 14 days of pretreatment = CT at 14 days after initial administration - CT at first administration (Eq. 2a).During 10 days of DEXA treatment = CT at the last day of DEXA treatment - CT at the first day DEXA treatment^a^ (Eq. 2b). ^a^A total of 2 weeks after pretreatment.After 24 days of treatment = CT at sacrifice - CT on the first day of pretreatment (Eq. 2c).

Calf muscle strength measurements
---------------------------------

A total of 1 h after the last dose of oxymetholone, vehicle or EAP was administered (10 days after the initial DEXA treatment), the calf muscle strengths of individual mice were measured as tensile strengths using a computerized testing machine (SV-H1000, Japan Instrumentation System Co., Ltd., Tokyo, Japan) in Newtons (N) according to established methods ([@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245]). Briefly, animals were restrained in the machine using two separate 1-0 silk suture ties on the chest and left ankle, and the peak tensile loads were documented as calf muscle strengths during knee angle reach of 0° (10--20-mm distance).

Gastrocnemius muscle weight measurements
----------------------------------------

After gastrocnemius muscle thickness was measured following sacrifice, the gastrocnemius muscles were separated carefully from the tibia and fibula bones. The weights of individual gastrocnemius muscles were measured in g (absolute wet-weights) using an electronic balance, and to reduce the differences from individual body weights, relative weights (% of body weights) were calculated according to body weight at sacrifice and absolute weight, following [equation 3](#fd1-ijmm-41-03-1245){ref-type="disp-formula"}.
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Serum biochemistry
------------------

To obtain sera for biochemical analysis, blood samples were collected on the day of sacrifice using a separation tube, and were then centrifuged at 600 × g for 10 min at ambient temperature. Separated serum samples were stored at −150°C in an ultra-deep freezer until further analysis. Serum creatine, creatine kinase (CK) and lactate dehydrogenase (LDH) levels were measured using an auto analyzer (Dri-Chem NX500i; FUJIFILM Medical Systems U.S.A., Inc., Stamford, CT, USA).

Antioxidant defense systems
---------------------------

Following muscle mass measurements, gastrocnemius muscles were separated and the malondialdehyde (MDA), glutathione (GSH) and reactive oxygen species (ROS) contents, and superoxide dismutase (SOD) and catalase (CAT) enzyme activities were assessed in individual muscles. Separated gastrocnemius muscles were weighed and homogenized in ice-cold 0.01 M Tris-HCl (pH 7.4), after which they were centrifuged at 12,000 × g for 15 min at ambient temperature, as described previously ([@b54-ijmm-41-03-1245]). Muscle tissue homogenates were stored at −150°C in an ultra-deep freezer until analysis. The degree of gastrocnemius muscle lipid peroxidation was measured by assessing MDA values using the thiobarbituric acid test at 525 nm using a UV/vis spectrometer (Optizen POP; Mecasys Co., Ltd., Daejeon, South Korea) ([@b55-ijmm-41-03-1245]). The total protein contents were measured using the Lowry method ([@b56-ijmm-41-03-1245]), whereas bovine serum albumin (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used as a standard. ROS level analyses were performed using 2′,7′-dichlorofluorescein diacetate fluorescent dye as a probe and fluorescence density was measured at 490/520 nm according to the manufacturer's protocol (Cellular Reactive oxygen Species Detection assay kit; ab113851; Abcam, Cambridge, MA, USA); the measured optical density values were corrected to the protein contents of samples and were expressed as RFu/*μ*g^−1^ protein ([@b57-ijmm-41-03-1245]). In addition, prepared homogenates were mixed with 0.1 ml 25% trichloroacetic acid (EMD Millipore, Billerica, MA, USA) and were then centrifuged at 800 × g for 40 min at 4°C. GSH contents were measured at 412 nm using 2-nitrobenzoic acid (Sigma-Aldrich; Merck KGaA), and were expressed as mg/g^−1^ tissue ([@b58-ijmm-41-03-1245]). H~2~O~2~ decomposition in the presence of CAT was estimated at 240 nm ([@b59-ijmm-41-03-1245]). CAT activity was defined as the amount of enzyme required to decompose 1 nM H~2~O~2~ per min, at 25°C and pH 7.8, and the results are expressed as U/mg^−1^ protein. Furthermore, SOD activity was measured at 560 nm according to a protocol previously described by Sun *et al* ([@b60-ijmm-41-03-1245]), and was expressed as U/mg^−1^ protein. One unit of SOD enzymatic activity is equal to the amount of enzyme that diminishes the initial absorbance of nitroblue tetrazolium by 50% during 1 min.

RT-qPCR
-------

Total RNA was extracted from gastrocnemius muscles using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to previous studies ([@b9-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245],[@b61-ijmm-41-03-1245]). The RNA concentration and quality were determined using a CFX96™ Real-Time PCR Detection system using iTaq™ SYBR-Green (both from Bio-Rad Laboratories, Inc., Hercules, CA, USA). The samples were treated with recombinant DNase I (DNA-free DNA removal kit; Ambion, Austin, TX, USA) to remove possible DNA contamination. RNA was reverse-transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manu facturer's protocol. The PCR cycling conditions were as follows: Initial pre-denaturation of 95°C for 1 min, denaturation for 15 sec, annealing of 55--65°C for 20 sec and extension of 72°C for 30 sec. A total of 50 cycles were performed. 18S ribosomal RNA was used as an internal control. PCR primer sequences are listed in [Table I](#tI-ijmm-41-03-1245){ref-type="table"}. For quantitative analysis, the intact control muscle tissue was used as the control, and the relative expression of Atrogin-1, MuRF 1, PI3K p85α, Akt1, Adenosine A1R, TRPV4, Myostatin and SIRT1 was calculated using the 2^−ΔΔCt^ method ([@b62-ijmm-41-03-1245]).

Histopathology
--------------

Samples from gastrocnemius muscles were separated and fixed in 10% neutral buffered formalin, embedded in paraffin wax, sectioned (3--4 *μ*m), and stained with Sirius red for collagen fibers or hematoxylin and eosin for general histopathology ([@b63-ijmm-41-03-1245],[@b64-ijmm-41-03-1245]). Histopathological profiles were observed under a light microscope (Eclipse 80i; Nikon Corporation, Tokyo, Japan). Mean muscle fiber diameters (*μ*m/fiber) and collagen fiber-occupied regions (%/mm^2^) in muscle bundles were calculated using an automated image analyzer (iSolution FL, version 9.1; Brooke Anco Corporation, Cicero, NY, USA) in gastrocnemius muscle samples, according to previous studies ([@b9-ijmm-41-03-1245],[@b15-ijmm-41-03-1245],[@b21-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245],[@b63-ijmm-41-03-1245]) with some modifications.

Immunohistochemistry
--------------------

Following deparaffinization of gastrocnemius muscle histological sections, citrate buffer antigen retrieval was conducted as previously described ([@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245],[@b65-ijmm-41-03-1245]). Briefly, a staining dish containing 10 mM citrate buffer (pH 6.0) was preheated at 95--100°C in a water bath. Slides were immersed in the staining dish and incubated for 20 min prior to turning off the water bath. The staining dish was placed at room temperature and the slides were allowed to cool for 20 min. Subsequently, sections were immunostained using the avidin-biotin complex (ABC) method, to detect caspase-3, poly (ADP-ribose) polymerase (PARP), nitrotyrosine, 4-hydroxynonenal (4-HNE), inducible nitric oxide synthase (iNOS) and myostatin expression ([Table II](#tII-ijmm-41-03-1245){ref-type="table"}) according to previous studies ([@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245]). Briefly, endogenous peroxidase activity was blocked by incubation in methanol and 0.3% H~2~O~2~ for 30 min at ambient temperature, and non-specific binding was blocked with normal horse serum blocking solution (1:100; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 h at ambient temperature in a humidified chamber. Slides were incubated with primary antibodies ([Table II](#tII-ijmm-41-03-1245){ref-type="table"}) overnight at 4°C in a humidified chamber, and were then incubated with biotinylated universal secondary antibody \[1:50; Vectastain Elite ABC kit (PK-6200); Vector Laboratories, Inc.\] and ABC reagents (1:50; Vectastain Elite ABC kit, Vector Laboratories, Inc.) for 1 h at room temperature in a humidified chamber. Finally, sections were treated with a peroxidase substrate kit (Vector Laboratories, Inc.) for 3 min at room temperature. All of the sections were rinsed in 0.01 M PBS three times between steps. Cells or muscle fibers that exhibited \>20% immunoreactivity with each antibody were considered positive, and the mean numbers of caspase-3, PARP, nitrotyrosine, 4-HNE, iNOS and myostatin-immunoreactive fibers, as dispersed in 1 mm^2^ of muscle bundles, were counted using an image analysis process described by Kim *et al* ([@b26-ijmm-41-03-1245],[@b35-ijmm-41-03-1245]) with some modifications. The histopathologist was blinded to the group distribution when performing the analysis.

Statistical analysis
--------------------

All numerical values are expressed as the means ± SD of 8 mice. Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test ([@b66-ijmm-41-03-1245]). If the Levene test indicated no significant deviation from variance homogeneity, data were analyzed by one-way analysis of variance followed by least-significant differences multi-comparison test to determine which pairs of group comparisons were significantly different. In cases where significant deviations from variance homogeneity were observed with the Levene test, the non-parametric Kruskal-Wallis H-test was used. When a significant difference was observed with the Kruskal-Wallis H test, the Mann-Whitney U test was conducted to determine the specific pairs of group comparisons that were significantly different. Statistical analyses were conducted using SPSS 14K for Windows software (SPSS Inc., Chicago, IL, USA) ([@b67-ijmm-41-03-1245]). Statistical significances were set at P\<0.01 and P\<0.05. Percent changes between intact vehicle and DEXA control groups were calculated to assess the severities of catabolic muscle atrophy induced, and the percent changes between the DEXA control and test material-treated mice were calculated, in order to understand the efficacy of the test substances according to the following [equations 4](#fd2-ijmm-41-03-1245){ref-type="disp-formula"} and [5](#fd3-ijmm-41-03-1245){ref-type="disp-formula"}: $$\begin{array}{l}
{\text{Percentage~change~compared~to~the~intact~vehicle~control~group}\ (\%)\  =} \\
{\left\lbrack \frac{\text{Data~of~DEXA~control} - \text{Data~of~intact~vehicle~control}}{\text{Data~of~intact~vehicle~control}} \right\rbrack \times 100} \\
\end{array}$$ $$\begin{array}{l}
{\text{Percentage~change~compared~to~the~DEXA~control~group}\ (\%)\  =} \\
{\left\lbrack \frac{\text{Data~of~test~material~treated~mice} - \text{Data~of~DEXA~control}}{\text{Data~of~DEXA~control}} \right\rbrack \times 100} \\
\end{array}$$

Results
=======

Alterations in body weight
--------------------------

Significant decreases (P\<0.01) in body weight were demonstrated in the DEXA control mice compared with in the intact control mice from 5 days after initial DEXA treatment to sacrifice. Accordingly, body weight during the 10 days of DEXA treatment, and after the total 24-day experimental period, was significantly decreased (P\<0.01) in the DEXA control mice compared with in the intact vehicle control group. However, these decreases in body weight were significantly inhibited (P\<0.01) by treatment with oxymetholone and all three doses of EAP (100, 200 and 400 mg/kg) from 5 days after initial DEXA treatment to sacrifice. In addition, body weight after 10 days of DEXA treatment, and after the total 24-day experimental period, was significantly increased (P\<0.01) in the oxymetholone- and EAP-treated mice compared with in the DEXA control group. Anyway, no test material treatment-related alterations in body weight were detected compared with intact vehicle or DEXA control mice in this experiment. Treatment with EAP (100, 200 and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in body weight, in particular 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in body weight, which were comparable with the effects of 50 mg/kg oxymetholone ([Table III](#tIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 1](#f1-ijmm-41-03-1245){ref-type="fig"}).

Effects on calf thickness
-------------------------

Significant decreases (P\<0.01) in calf thickness were demonstrated in the DEXA control mice compared with in the intact control mice from 19 days after initial administration of the test substances to the day of sacrifice. Accordingly, calf thickness alterations after 10 days of DEXA treatment, and after the total 24-day test substance administration period, were also significantly decreased (P\<0.01) in the DEXA control mice compared with in the intact vehicle controls. However, 5 days after the initial DEXA treatment, these decreases in calf thickness were significantly inhibited (P\<0.01) by treatment with the three doses of EAP, and calf thickness during the 10 days of DEXA treatment, and the total 24-day test substance administration period, were also significantly increased (P\<0.01) in these groups compared with in the DEXA control group. Furthermore, 50 mg/kg oxymetholone-treated mice also exhibited significant increases (P\<0.01) in calf thickness from 5 days after the initial DEXA treatment, and also exhibited significant increases (P\<0.01) in calf thickness during the 10 days of DEXA treatment and the total 24-day test substance administration period. A dose of 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in calf thickness, which were comparable with the effects of 50 mg/kg oxymetholone ([Table IV](#tIV-ijmm-41-03-1245){ref-type="table"} and [Fig. 2](#f2-ijmm-41-03-1245){ref-type="fig"}).

Effects on gastrocnemius muscle thickness after muscle exposure
---------------------------------------------------------------

Significant decreases (P\<0.01) in gastrocnemius muscle thickness following muscle exposure were observed in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases (P\<0.01) in gastrocnemius muscle thickness were detected in the mice treated with oxymetholone and all three doses of EAP compared with in the DEXA control group. EAP (100, 200 and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in gastrocnemius muscle thickness. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on gastrocnemius muscle thickness, which were comparable with the effects of 50 mg/kg oxymetholone ([Figs. 3](#f3-ijmm-41-03-1245){ref-type="fig"} and [4](#f4-ijmm-41-03-1245){ref-type="fig"}).

Effects on gastrocnemius muscle mass
------------------------------------

Significant decreases (P\<0.01) in relative weights and absolute wet weights of gastrocnemius muscle mass were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases (P\<0.01) in gastrocnemius muscle weights were observed in the oxymetholone-treated and 100, 200 and 400 mg/kg EAP-treated mice compared with in the DEXA control group. EAP doses (100, 200, and 400 mg/kg) exhibited dose-dependent inhibitory effects on the DEXA-induced decreases in gastrocnemius muscle weights; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on gastrocnemius muscle weight, which were comparable with the effects of 50 mg/kg oxymetholone ([Fig. 5](#f5-ijmm-41-03-1245){ref-type="fig"}).

Effects on calf muscle strength
-------------------------------

Significant decreases (P\<0.01) in the tensile strength of calf muscles were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases (P\<0.01) in calf muscle strength were observed in oxymetholone-treated and 200 and 400 mg/kg EAP-treated mice compared with in the DEXA control group. In addition, 100 mg/kg EAP-treated mice exhibited non-significant increases in calf muscle strength compared with in the DEXA control mice. EAP (100, 200 and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in calf muscle strength; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength, which were comparable with the effects of 50 mg/kg oxymetholone ([Fig. 6](#f6-ijmm-41-03-1245){ref-type="fig"}).

Effects on serum biochemistry
-----------------------------

Significant increases (P\<0.01) in serum CK and creatine levels, and decreases in serum LDH levels, were demonstrated in the DEXA control mice compared with in the intact vehicle control mice. However, significant decreases (P\<0.05) in serum CK and creatine levels were observed in oxymetholone- and EAP-treated mice compared with in the DEXA control group, alongside significant increases (P\<0.05) in serum LDH levels. EAP (100, 200, and 400 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced increases in serum CK and creatine levels, and decreases in serum LDH levels. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on serum CK and creatine level elevations, and decreases in serum LDH levels, which were comparable with the effects of 50 mg/kg oxymetholone ([Table V](#tV-ijmm-41-03-1245){ref-type="table"}).

Effects on gastrocnemius muscle antioxidant defense systems Alterations in muscle MDA levels
--------------------------------------------------------------------------------------------

Significant increases (P\<0.01) in MDA levels were observed in the DEXA control group compared with in the intact control group. However, the elevations in MDA levels were significantly (P\<0.01) and dose-dependently decreased following treatment with EAP. Gastrocnemius muscle lipid peroxidation in oxymetho-lone-treated mice was also significantly decreased (P\<0.01) compared with in the control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in muscle lipid peroxidation, which were comparable with the effects of 50 mg/kg oxymetholone ([Table VI](#tVI-ijmm-41-03-1245){ref-type="table"}).

Alterations in muscle ROS content
---------------------------------

Significant increases (P\<0.01) in muscle ROS content were observed in the DEXA control group compared with in the intact control group. However, elevated ROS levels were significantly and dose-dependently decreased (P\<0.01) following treatment with EAP. In addition, gastrocnemius muscle ROS levels were significantly (P\<0.01) inhibited in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced muscle ROS elevations, which were comparable with the effects of oxymetholone ([Table VI](#tVI-ijmm-41-03-1245){ref-type="table"}).

Alterations in muscle GSH content
---------------------------------

Significant decreases (P\<0.01) in the levels of the endogenous antioxidant, GSH, were detected in the DEXA control group compared with in the intact control group. However, these decreases in muscle GSH were significantly (P\<0.05) inhibited following 24 days of oral treatment with oxymetholone, and 100, 200 and 400 mg/kg EAP. EAP increased gastrocnemius muscle GSH content in a dose-dependent manner compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in muscle GSH content, which were comparable with the effects of oxymetho-lone ([Table VI](#tVI-ijmm-41-03-1245){ref-type="table"}).

Alterations in muscle SOD activity
----------------------------------

Significant decreases (P\<0.01) in the activity levels of the endogenous antioxidant enzyme, SOD, were detected in the DEXA control group compared with in the intact control group. However, significant increases (P\<0.01) in SOD activity were observed in oxymetholone-treated, and 100, 200 and 400 mg/kg EAP-treated mice compared with in the DEXA control mice. EAP exerted dose-dependent increases on SOD activity in gastrocnemius muscles compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in SOD activity levels, which were comparable with the effects of 50 mg/kg oxymetholone ([Table VI](#tVI-ijmm-41-03-1245){ref-type="table"}).

Alterations in muscle CAT activity
----------------------------------

Significant decreases (P\<0.01) in the activity levels of the endogenous antioxidant enzyme, CAT, were detected in the DEXA control group compared with in the intact control group. However, these decreases in muscle CAT activity were significantly and dose-dependently inhibited (P\<0.01) following 24 days of oral treatment with EAP. Gastrocnemius muscle CAT activity levels in 50 mg/kg oxymetholone-treated mice were also significantly increased (P\<0.01) compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in muscle CAT activity levels, which were comparable with the effects of 50 mg/kg oxymetholone ([Table VI](#tVI-ijmm-41-03-1245){ref-type="table"}).

Effects on gastrocnemius muscle mRNA expression
-----------------------------------------------

Significant alterations (P\<0.01) in the mRNA expression levels of atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 were detected in the gastrocnemius muscles of the DEXA control group compared with in the intact control group. However, these alterations in muscle atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 expression were significantly reversed (P\<0.05), in a dose-dependent manner, by treatment with EAP. In addition, the mRNA expression levels of atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 in gastrocnemius muscle tissues, were significantly reversed in 50 mg/kg oxymetholone-treated mice (P\<0.01) compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable activities on DEXA-induced alterations in muscle atrogin-1, MuRF1, PI3K, Akt1, A1R, TRPV4, myostatin and SIRT1 mRNA expression, which were comparable with the effects of 50 mg/kg oxymetholone ([Table VII](#tVII-ijmm-41-03-1245){ref-type="table"}).

Effects on gastrocnemius muscle histopathology
----------------------------------------------

Marked alterations associated with catabolic muscle atrophy, including focal fibrosis in muscle bundles, microvacuolation and diminished muscle fibers, were induced by treatment with DEXA in the control mice. Accordingly, significant decreases (P\<0.01) in mean muscle fiber diameters and increases in collagen fiber-occupied region percentages in muscle bundles were detected in the DEXA control mice compared with in the intact control mice. However, these DEXA treatment-associated catabolic alterations were significantly (P\<0.05) and dose-dependently decreased following treatment with EAP. The muscle atrophy-associated alterations were also significantly inhibited (P\<0.01) in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in mean muscle fiber diameters and increases in collagen fiber-occupied regions in muscle bundles, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 7](#f7-ijmm-41-03-1245){ref-type="fig"}).

Effects on gastrocnemius muscle immunohistochemistry
----------------------------------------------------

### Alterations in caspase-3-immunolabelled muscle fibers

Significant increases (P\<0.01) in caspase-3 (apoptotic marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.01) these DEXA-induced increases in caspase-3-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P\<0.01) the number of caspase-3-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in caspase-3 immunoreactivity, which were comparable with the effects of 50 mg/kg oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 8](#f8-ijmm-41-03-1245){ref-type="fig"}).

### Alterations in PARP-immunolabelled muscle fibers

Significant increases (P\<0.01) in PARP (apoptotic marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.01) these DEXA-induced increases in PARP-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P\<0.01) the number of PARP-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in PARP immunoreactivity, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 8](#f8-ijmm-41-03-1245){ref-type="fig"}).

### Alterations in nitrotyrosine-immunolabelled muscle fibers

Significant increases (P\<0.01) in nitrotyrosine (iNOS-associated oxidative stress marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.01) these DEXA-induced increases in the number of nitrotyrosine-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P\<0.01) the number of nitrotyrosine-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in nitrotyrosine immunoreactivity, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 9](#f9-ijmm-41-03-1245){ref-type="fig"}).

### Alterations in 4-HNE-immunolabelled muscle fibers

Significant increases (P\<0.01) in 4-HNE (lipid peroxidation marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.01) these DEXA-induced increases in muscle 4-HNE-immunoreactive fibers. Oxymetholone also significantly decreased (P\<0.01) the number of 4-HNE-positive muscle fiber compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in 4-HNE-immunoreactive fibers, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 9](#f9-ijmm-41-03-1245){ref-type="fig"}).

### Alterations in iNOS-immunolabelled muscle fibers

Significant increases (P\<0.01) in iNOS (oxidative stress marker) immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.01) these DEXA-induced increases in muscle iNOS-immunoreactive fibers. Oxymetholone also significantly decreased (P\<0.01) the number of iNOS-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in iNOS-immunoreactive fibers, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 10](#f10-ijmm-41-03-1245){ref-type="fig"}).

### Alterations in myostatin-immunolabelled muscle fibers

Significant increases (P\<0.01) in myostatin immunoreactivity in gastrocnemius muscle bundles were observed in the DEXA control mice. EAP significantly and dose-dependently reduced (P\<0.05) these DEXA-induced increases in myostatin-immunoreactive muscle fibers. Oxymetholone also significantly decreased (P\<0.01) the number of myostatin-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in myostatin-immunoreactive fibers, which were comparable with the effects of oxymetholone ([Table VIII](#tVIII-ijmm-41-03-1245){ref-type="table"} and [Fig. 10](#f10-ijmm-41-03-1245){ref-type="fig"}).

Discussion
==========

Atrophy begins with a decrease in muscle tension, which is associated with reduced protein synthesis and increased protein degradation ([@b68-ijmm-41-03-1245]). Four types of proteolytic degradation are involved in muscle atrophy: Calpain calcium-dependent signaling, lysosomal proteases (cathepsins), the ubiquitin proteasome pathway and the caspase signaling system ([@b6-ijmm-41-03-1245],[@b68-ijmm-41-03-1245]--[@b70-ijmm-41-03-1245]). There is a common genetic program involved in muscle proteolysis regardless of its etiology; however, distinct signaling pathways are involved to modulate the system ([@b6-ijmm-41-03-1245],[@b69-ijmm-41-03-1245],[@b71-ijmm-41-03-1245]). Oxidative stress is a well-known and important inducer of muscle atrophy in response to disuse and in catabolic muscle cachexia ([@b71-ijmm-41-03-1245]). In addition, apoptosis and loss of muscle fibers are also involved in the early phase of muscle atrophy, regardless of etiology ([@b72-ijmm-41-03-1245],[@b73-ijmm-41-03-1245]).

Glucocorticoid-induced catabolic muscle atrophy is characterized by a reduction and degradation in protein content, organelles, cytoplasm, fiber diameter, resistance to fatigue and muscle strength ([@b16-ijmm-41-03-1245],[@b21-ijmm-41-03-1245],[@b23-ijmm-41-03-1245],[@b28-ijmm-41-03-1245],[@b74-ijmm-41-03-1245]). Glucocorticoids are immunosuppressants that are clinically used to suppress swelling and acute inflammation. Millions of people take glucocorticoids as chronic therapy to treat various diseases, including asthma, rheumatoid arthritis, primary or secondary adrenal insufficiency, and organ transplants ([@b23-ijmm-41-03-1245]). Common side effects of glucocorticoids include nervousness, insomnia, gastrointestinal upset, immunosuppression, arthralgia, myopathy and edema ([@b75-ijmm-41-03-1245]). Glucocorticoids have been in commercial use for \>50 years ([@b76-ijmm-41-03-1245]); however, their prolonged use is associated with myopathy, particularly with prolonged high doses. Long-term glucocorticoid therapy enhances the risk of muscle weakness and myopathy by 50% ([@b77-ijmm-41-03-1245],[@b78-ijmm-41-03-1245]). The characteristic features of myopathy include weakness and muscle atrophy, oxidative stress, mitochondrial dysfunction and insulin resistance. Histological alterations associated with muscle atrophy include loss of myosin filaments in sarcomeres, type II specific atrophy of muscle fibers, preservation of Z-bands and thin filaments, and necrosis ([@b74-ijmm-41-03-1245]). Steroid-induced myopathy is not only associated with the use of fluorinated steroids, including triamcinolone, β-methasone and DEXA, but can also be caused by non-fluorinated steroids, such as hydrocortisone and prednisolone ([@b79-ijmm-41-03-1245]). In the present study, the potential beneficial skeletal muscle-preserving effects of EAP were examined in a mouse model of DEXA-induced catabolic muscle atrophy.

All of the intact vehicle control mice exhibited normal body weight gain throughout the experimental period, including during the 10 days of acclimation ([@b80-ijmm-41-03-1245],[@b81-ijmm-41-03-1245]). The DEXA-induced decreases in body weight detected in the present study were considered to be related to cachexia, due to the potent catabolic effects of DEXA ([@b82-ijmm-41-03-1245],[@b83-ijmm-41-03-1245]). Conversely, the increased body weight detected in mice treated with EAP may be associated with the known immunomodulatory effects of EAP ([@b45-ijmm-41-03-1245],[@b84-ijmm-41-03-1245]). Generally, good growth patterns are associated with an enhanced immune system ([@b85-ijmm-41-03-1245],[@b86-ijmm-41-03-1245]), which is induced by EAP administration ([@b84-ijmm-41-03-1245]). Oxymetholone is a 17α-alkylated anabolic-androgenic steroid ([@b33-ijmm-41-03-1245],[@b34-ijmm-41-03-1245]), which may inhibit the catabolic cachexia-associated decreases in body weight induced by glucocorticoid treatment ([@b87-ijmm-41-03-1245]--[@b89-ijmm-41-03-1245]).

Overuse of glucocorticoids can facilitate catabolic muscle atrophy, which is characterized by decreased fiber diameter, and reduced and degraded protein contents ([@b16-ijmm-41-03-1245],[@b21-ijmm-41-03-1245],[@b23-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b28-ijmm-41-03-1245],[@b74-ijmm-41-03-1245]). In the present study, decreases in calf thickness were detected 5 days after the initial DEXA treatment in DEXA-treated mice, alongside decreased gastrocnemius muscle thickness, and calf muscle strength and weight at sacrifice, as a result of catabolic muscle atrophy. Conversely, oral administration of 100, 200 and 400 mg/kg EAP, and 50 mg/kg oxymetholone, inhibited DEXA-induced decreases in calf muscle strength and thickness, and gastrocnemius muscle thickness and weight, thus indicating that oxymetholone and EAP may reverse the DEXA-induced atrophic alterations in calf muscles.

Creatine is a naturally occurring nitrogenous organic acid that assists in the supply of energy to the entire body, particularly muscle cells. Creatine is synthesized in the kidney and liver; however, muscles do not possess the ability to synthesize creatine. Creatine is stored in the muscle, according to a concentration gradient, via a specific active transport mechanism from the plasma ([@b90-ijmm-41-03-1245]). Skeletal muscle is a large and relatively constant reservoir of creatine in the body ([@b91-ijmm-41-03-1245],[@b92-ijmm-41-03-1245]). Creatine is constantly metabolized to its non-ionic cyclic derivative creatinine, over 1.7% of creatine is metabolized per day via non-enzymatic hydrolytic cyclization ([@b93-ijmm-41-03-1245],[@b94-ijmm-41-03-1245]). Creatinine rapidly diffuses from the muscle into the plasma and is transferred to the urine, with no uptake into muscles ([@b90-ijmm-41-03-1245],[@b95-ijmm-41-03-1245]). Therefore, plasma creatine levels can be used as a serum biochemical indicator for skeletal muscle damage, activity or muscle quantity ([@b26-ijmm-41-03-1245],[@b96-ijmm-41-03-1245],[@b97-ijmm-41-03-1245]). In the present study, marked increases in serum creatine levels were verified alongside other DEXA-associated catabolic muscle atrophic alterations; this finding was similar to those of previous studies ([@b16-ijmm-41-03-1245],[@b26-ijmm-41-03-1245]). Oral administration of 100, 200 and 400 mg/kg EAP significantly and dose-dependently limited the DEXA-induced increases in serum creatine levels. Particularly, 400 mg/kg EAP exhibited favorable inhibitory effects on serum creatine level elevations; these effects were comparable with those of 50 mg/kg oxymetholone, thus indicating that EAP exerts positive muscle-preserving effects against glucocorticoid-induced atrophy.

The medical significance of LDH is evident due to its extensive presence in body tissues, including heart muscle and blood cells. CK is an enzyme expressed by various tissues and cell types, which is involved in the conversion of creatine and the consumption of adenosine. Since LDH and CK are released during tissue damage, they are considered markers of common disease and injuries, particularly muscle damage. Plasma activities of CK and LDH have been used commonly as markers of muscle tissue damage ([@b26-ijmm-41-03-1245],[@b98-ijmm-41-03-1245],[@b99-ijmm-41-03-1245]). They are also markedly elevated in animals with disused muscle atrophy ([@b100-ijmm-41-03-1245]). In a DEXA-induced animal model of catabolic muscle atrophy, marked elevations in serum CK levels were noted; however, serum LDH levels were generally decreased due to reduced physiological activity and skeletal muscle fiber concentration ([@b24-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b101-ijmm-41-03-1245]). Significantly elevated serum CK levels, indicating decreases in serum LDH levels and muscle damage, thus signifying reduced muscle activity, were demonstrated in the DEXA control mice in the present study. However, significant and dose-dependent decreases in serum CK and increases in serum LDH levels were detected in 100, 200, and 400 mg/kg EAP-treated mice; these effects were comparable with those of 50 mg/kg oxymetholone. In particular, 400 mg/kg EAP exhibited favorable and potent muscle-preserving effects.

Lipid peroxidation can harm surrounding tissues due to the release of various toxic substances ([@b102-ijmm-41-03-1245]), and oxidative stress is a significant inducer of muscle atrophy ([@b71-ijmm-41-03-1245]). Inhibition of increased lipid peroxidation protects muscles against atrophic alterations ([@b57-ijmm-41-03-1245],[@b103-ijmm-41-03-1245],[@b104-ijmm-41-03-1245]). Nitrotyrosine, which is a product of tyrosine nitration that has been detected in numerous pathological disorders, is known as a marker of iNOS-dependent nitrate stress ([@b105-ijmm-41-03-1245]--[@b107-ijmm-41-03-1245]). In addition, it has been demonstrated to damage antioxidant defense systems in muscle tissues; this was associated with glucocorticoid-induced catabolic muscle atrophic alterations ([@b26-ijmm-41-03-1245],[@b71-ijmm-41-03-1245],[@b108-ijmm-41-03-1245]). In the present study, EAP dose-dependently protected the gastrocnemius muscle against DEXA-triggered oxidative stress, reduced DEXA-induced increases in lipid peroxidation and ROS formation, increased DEXA-induced decreases in CAT and SOD activities and GSH contents, and reduced DEXA-induced increases in nitrotyrosine and 4-HNE-immunolabelled muscle fibers. Oxymetholone also exerted strong antioxidative effects against DEXA-induced depletion of antioxidant defense systems, consistent with other studies on anabolic steroids ([@b109-ijmm-41-03-1245],[@b110-ijmm-41-03-1245]) and previous results in glucocorticoid-induced catabolic muscle atrophic mice ([@b26-ijmm-41-03-1245]).

Apoptosis and muscle fiber damage are associated with the early phase of muscle atrophy regardless of etiology ([@b72-ijmm-41-03-1245],[@b73-ijmm-41-03-1245]), and caspase-3 and PARP serve key roles in apoptosis ([@b111-ijmm-41-03-1245],[@b112-ijmm-41-03-1245]). Increases in the number of caspase-3 and PARP-immunoreactive muscle fibers in muscle bundles indicate apoptosis and related damage ([@b26-ijmm-41-03-1245],[@b113-ijmm-41-03-1245],[@b114-ijmm-41-03-1245]). Furthermore, treatment with glucocorticoids has been reported to induce marked apoptosis in muscles ([@b23-ijmm-41-03-1245],[@b26-ijmm-41-03-1245]). Therefore, EAP-induced dose-dependent inhibition of caspase-3 and PARP immunore-activity in DEXA-treated gastrocnemius muscle bundles may provide direct evidence that EAP can preserve muscle mass through inhibitory effects against DEXA-induced muscle fiber apoptosis.

Muscle structure and mass are evaluated by the equilibrium between protein synthesis and degradation ([@b70-ijmm-41-03-1245]). Protein degradation, which is responsible for muscle wasting, is triggered by ATP-ubiquitin-dependent proteolysis ([@b9-ijmm-41-03-1245]). A previous study reported that the muscle-specific E3 ubiquitin ligases, including MuRF1 and atrogin-1, are important for muscle atrophy ([@b6-ijmm-41-03-1245]). In addition, it has been revealed that the expression levels of MuRF1 and atrogin-1 are increased in atrophic skeletal muscles, and mice deficient in MuRF1 or atrogin-1 are resistant to muscle atrophy ([@b5-ijmm-41-03-1245],[@b115-ijmm-41-03-1245],[@b116-ijmm-41-03-1245]). In addition, marked increases in the mRNA expression levels of MuRF1 and atrogin-1 have been observed in glucocorticoid-induced catabolic atrophic muscles ([@b16-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b28-ijmm-41-03-1245]). In the present study, marked elevations in the mRNA expression levels of MuRF1 and atrogin-1 in gastrocnemius muscles were detected in the DEXA control group compared with in the intact vehicle control group; however, these elevations were dose-dependently inhibited following treatment with EAP, providing direct evidence to suggest that EAP exerts muscle-protective effects apparently mediated through downregulation of atrogin-1 and MuRF1. In particular, 400 mg/kg EAP exhibited favorable inhibitory effects on muscle atrogin-1 and MuRF1 mRNA expression; these effects were comparable with those of oxymetholone.

Protein synthesis is activated by the insulin-like growth factor 1 (IGF-1)/PI3K/Akt pathway ([@b6-ijmm-41-03-1245],[@b70-ijmm-41-03-1245]). PI3K, which is initiated by IGF or insulin, in turn activates the serine/threonine kinase Akt ([@b69-ijmm-41-03-1245]). Marked downregulation of PI3K and Akt1 mRNA expression were detected in DEXA-treated mice with catabolic muscle atrophic alterations; this finding was consistent with the results of a previous study ([@b26-ijmm-41-03-1245]). Conversely, EAP dose-dependently upregulated the mRNA expression levels of Akt1 and PI3K compared with in the DEXA control group, which indicated that EAP may resist glucocorticoid-induced muscle atrophy and activate muscle protein synthesis; these effects were comparable with those of oxymetholone. Notably, 400 mg/kg EAP exhibited favorable upregulating effects on Akt1 and PI3K mRNA expression, comparable with those of oxymetholone.

Adenosine modulates numerous physiological functions in various tissues, including skeletal muscle and the cardiovascular system ([@b117-ijmm-41-03-1245]--[@b119-ijmm-41-03-1245]). Adenosine is considered to be involved in the synergistic effects of contraction- and insulin-stimulated glucose uptake in skeletal muscle, and in the regulation of blood flow to skeletal muscle ([@b120-ijmm-41-03-1245],[@b121-ijmm-41-03-1245]). Specific adenosine receptors are associated with facilitation of the physiological effects of adenosine ([@b122-ijmm-41-03-1245]). TRPV4 is a member of the TRP channel superfamily ([@b123-ijmm-41-03-1245],[@b124-ijmm-41-03-1245]), which serves an osmosensory or mechanosensory role in numerous musculoskeletal tissues, and prevents muscle atrophy and bone loss ([@b124-ijmm-41-03-1245],[@b125-ijmm-41-03-1245]). Subcutaneous treatment with DEXA significantly decreased the mRNA expression levels of TRPV4 and A1R in gastrocnemius muscle, which may be associated with catabolic muscle atrophy-related proteolysis; these findings were similar to those of a previous study ([@b26-ijmm-41-03-1245]). EAP dose-dependently upregulated A1R and TRPV4 mRNA expression compared with in the DEXA control group, providing direct evidence that 400 mg/kg EAP can increase muscle growth and resist DEXA-induced catabolic muscle atrophy; these effects were comparable with those of 50 mg/kg oxymetholone.

Myostatin is a secreted growth differentiation factor that inhibits growth and muscle differentiation in myogenesis. It is a powerful negative controller of muscle growth ([@b9-ijmm-41-03-1245],[@b16-ijmm-41-03-1245]). The sirtuin protein family (SIRT1-7) possesses ADP ribosyltransferase activity and/or NAD^+^-dependent deacetylase activity ([@b126-ijmm-41-03-1245]). SIRT1 controls numerous biological processes, including differentiation, cell proliferation, metabolism and apoptosis ([@b127-ijmm-41-03-1245]). In addition, it regulates transcription of peroxisome proliferator-activated receptor-γ co-activator 1α in skeletal muscle ([@b128-ijmm-41-03-1245]) and inhibits muscle regeneration, which causes cachexia ([@b129-ijmm-41-03-1245]). In catabolic muscle atrophy, the mRNA expression levels of SIRT1 and myostatin have been detected alongside decreases in muscle mass ([@b16-ijmm-41-03-1245],[@b25-ijmm-41-03-1245],[@b26-ijmm-41-03-1245],[@b130-ijmm-41-03-1245]); similar findings were induced with DEXA treatment in the present study. However, elevations in the expression levels of SIRT1, a representative inhibitor of muscle regeneration, and myostatin, a strong negative regulator of muscle growth, were dose-dependently inhibited by treatment with EAP. In addition, EAP dose-dependently inhibited increases in myostatinimmunoreactive fibers, as determined by immunohistochemical analysis, providing evidence of muscle-shielding effects via downregulation of SIRT1 and myostatin. Notably, 400 mg/kg EAP exhibited favorable inhibitory effects on muscle myostatin and SIRT1 mRNA expression, and myostatin immunoreactivity in muscle fibers; these effects were comparable with those of 50 mg/kg oxymetholone.

Glucocorticoid-induced catabolic muscle atrophic alterations have been reported to induce marked histopatho-logical alterations, including microvacuolation, diminished muscle fiber diameter, fibrosis and collagen deposition, as well protein degradation ([@b15-ijmm-41-03-1245],[@b21-ijmm-41-03-1245],[@b26-ijmm-41-03-1245]); these alterations were observed in the present study. However, in the present study, muscle atrophy-associated alterations were reduced by treatment with oxymetholone or EAP. These findings suggested that oxymetholone or EAP may protect muscles against DEXA-induced catabolic atrophy. EAP exhibited favorable inhibitory effects on histopathological muscle fibrosis and atrophic alterations, which were compared with the effects of oxymetholone.

In conclusion, EAP exerted favorable ameliorating effects on DEXA-induced catabolic muscle atrophy via anti-inflammatory and antioxidant effects, which were mediated by modulation of the expression of genes associated with muscle protein synthesis (Akt1, PI3K, A1R and TRPV4) and degradation (atrogin-1, MuRF1, myostatin and SIRT1). Therefore, EAP may be helpful in improving various muscle atrophy conditions with various etiologies. Notably, 400 mg/kg EAP exhibited favorable muscle-protective effects against DEXA-induced catabolic muscle atrophy, which were comparable with the effects of 50 mg/kg oxymetholone.

The present study was financially supported by the Ministry of Trade, Industry, and Energy, Korea, under the 'Regional Specialized Industry Development Program' (grant no. R0005069; Development of functional food products for improving the locomotive syndrome using black yeast β-glucan) supervised by the Korea Institute for Advancement of Technology.

![Body weight alterations in mice with DEXA-induced muscle atrophy. Significant decreases in body weight were detected in the DEXA control mice compared with in the intact control mice from 5 days after initial DEXA treatment, 19 days after initial administration (dotted arrow). However, these decreases in body weight were significantly inhibited by treatment with oxymetholone and all three doses of EAP (400, 200 and 100 mg/kg), from 5 days after initial DEXA treatment (arrowhead) to sacrifice. EAP 400, 200 and 100 mg/kg exhibited clear dose-dependent inhibitory effects on DEXA-induced decreases in body weight, particularly EAP 400 mg/kg, which exerted comparable effects to oxymetholone (50 mg/kg). No test material treatment-associated body weight alterations were detected compared with in the intact vehicle and DEXA control mice during the 14-day pretreatment period. Data are presented as the mean ± standard deviation of 8 mice. Day -1 and 24 indicates 1 day prior to initial administration of test materials and the day of sacrifice, respectively. Day 0 indicates initiation of test material administration, at 2 weeks prior to initial DEXA treatment. All animals were fasted overnight prior to initial administration of test materials and sacrifice (arrows). ^a^P\<0.01 compared with the intact control group, as determined by LSD test. ^b^P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference. Results were significant at 24 days](IJMM-41-03-1245-g00){#f1-ijmm-41-03-1245}

![Calf thickness alterations in mice with DEXA-induced muscle atrophy. Significant decreases in calf thickness were revealed in the DEXA control mice compared with in the intact control mice from 19 days after the initial test substance administration to the day of sacrifice (dotted arrow). However, these decreases in calf thicknes were significantly and dose-dependently inhibited by treatment with all three doses of EAP (400, 200 and 100 mg/kg) from 5 days after the intial DEXA treatment (arrowhead). In addition, 50 mg/kg oxymetholone-treated mice also exhibited significant increases in calf thickness from 5 days after the intial DEXA treatment compared with in the DEXA control mice (arrowhead). EAP (400 mg/kg) exhibited favorable inhibitory activities on DEXA-induced decreases in calf thickness, as comparable to those of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Day -1 and 24 indicates 1 day prior to initial administration of test materials and the day of sacrifice, respectively. Day 0 indicates initiation of test material administration, at 2 weeks prior to initial DEXA treatment. All animals were fasted overnight prior to initial administration of test materials and sacrifice (arrows). ^a^P\<0.01 compared with the intact control group, as determined by LSD test. ^b^P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference. Results were significant at 24 days](IJMM-41-03-1245-g01){#f2-ijmm-41-03-1245}

![Alterations in calf muscle mass in mice with DEXA-induced muscle atrophy. Marked decreases in calf muscle mass following muscle exposure (arrows) were detected in the DEXA control mice compared with in the intact vehicle control mice. However, marked increases in calf muscle mass were detected in the oxymetholone- and EAP-treated mice compared with in the DEXA control group. EAP (400, 200 and 100 mg/kg) exhibited obvious dose-dependent inhibitory effects on DEXA-induced decreases in gastrocnemius muscle mass; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in gastrocnemius muscle mass, which were comparable with those of 50 mg/kg oxymetholone. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001. Scale bars=9 mm.](IJMM-41-03-1245-g02){#f3-ijmm-41-03-1245}

![Alterations in gastrocnemius muscle thickness following muscle exposure in mice with DEXA-induced muscle atrophy. Significant decreases in gastrocnemius muscle thickness following muscular exposure were detected in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases in gastrocnemius muscle thickness were observed in oxymetholone- and EAP-treated mice compared with in the DEXA control group. EAP (400, 200 and 100 mg/kg) exhibited marked dose-dependent inhibitory effects on DEXA-induced decreases in gastroc-nemius muscle thickness; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in gastrocnemius muscle thickness, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. ^a^P\<0.01 compared with the intact control group, as determined by LSD test. ^b^P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference.](IJMM-41-03-1245-g03){#f4-ijmm-41-03-1245}

![Alterations in gastrocnemius muscle weight in mice with DEXA-induced muscle atrophy. Significant decreases in absolute wet-weights and relative weights of gastrocnemius muscle mass were revealed in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases in gastrocnemius muscle mass weights were observed in oxymetholone- and EAP-treated mice compared with in the DEXA control group. EAP (400, 200 and 100 mg/kg) exhibited dose-dependent inhibitory effects on DEXA-induced decreases in gastrocnemius muscle weights; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in gastrocnemius muscle weights, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. ^a^P\<0.01 and ^b^P\<0.05 compared with the intact control group, as determined by LSD test. ^c^P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference.](IJMM-41-03-1245-g04){#f5-ijmm-41-03-1245}

![Alterations in calf muscle strength in mice with DEXA-induced muscle atrophy. Significant decreases in the tensile strength of calf muscles were revealed in the DEXA control mice compared with in the intact vehicle control mice. However, significant increases in calf muscle strength were observed in the 50 mg/kg oxymetholone-treated and 400 and 200 mg/kg EAP-treated mice compared with in the DEXA control group. In addition, 100 mg/kg EAP-treated mice exhibited non-significant increases in calf muscle strength compared with in the DEXA control mice. EAP (400, 200 and 100 mg/kg) exhibited clear dose-dependent inhibitory effects on DEXA-induced decreases in calf muscle strength; in particular, 400 mg/kg EAP exhibited favorable inhibitory activities on decreases in calf muscle strength, which were comparable with the effects of oxymetholone (50 mg/kg). Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in deionized distilled water. ^a^P\<0.01 compared with the intact control group, as determined by LSD test. ^b^P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference.](IJMM-41-03-1245-g05){#f6-ijmm-41-03-1245}

![Representative gastrocnemius muscle histology. Marked catabolic muscular atrophy-associated alterations, including microvacuolation, reduced muscle fibers and focal fibrosis in muscle bundles were induced by treatment with DEXA; accordingly, significant decreases in mean muscle fiber diameters and increases in collagen fiber-occupied region percentages in muscle bundles were detected in the DEXA control mice compared with in the intact control mice. However, these DEXA treatment-associated catabolic atrophic alterations to gastrocnemius muscles were significantly and dose-dependently decreased following treatment with EAP. In addition, the muscular atrophic alterations were significantly reduced in 50 mg/kg oxymetholone-treated mice compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced decreases in mean muscle fiber diameter and increases in collagen fiber-occupied region percentages in muscle bundles, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 *μ*m. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001.](IJMM-41-03-1245-g06){#f7-ijmm-41-03-1245}

![Representative gastrocnemius muscle caspase-3 and PARP immunoreactivity. Marked increases in the immunoreactivity of the apoptotic markers, caspase-3 and PARP, were detected in gastrocnemius muscle bundles from DEXA control mice. EAP dose-dependently and significantly reduced these DEXA-induced increases in muscular caspase-3- and PARP-immunoreactive muscle fibers. In addition, oxymetholone (50 mg/kg) significantly reduced the number of caspase-3- and PARP-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in caspase-3- and PARP-immunoreactive fibers, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 *μ*m. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; PARP, cleaved poly(ADP-ribose) polymerase.](IJMM-41-03-1245-g07){#f8-ijmm-41-03-1245}

![Representative gastrocnemius muscle nitrotyrosine and 4-HNE immunoreactivity. Marked increases in the immunoreactivity of the oxidative stress marker, nitrotyrosine, and the lipid peroxidation marker, 4-HNE, were detected in the gastrocnemius muscle bundles from DEXA control mice. However, EAP dose-dependently and significantly reduced these DEXA-induced increases in nitrotyrosine- and 4-HNE-immunoreactive fibers. In addition, oxymetholone (50 mg/kg) significantly reduced the number of nitrotyrosine- and 4-HNE-positive muscle fibers as compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in nitrotyrosine- and 4-HNE-immunoreactive fibers, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 *μ*m. 4-HNE, 4-hydroxynonenal; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001.](IJMM-41-03-1245-g08){#f9-ijmm-41-03-1245}

![Representative gastrocnemius muscle iNOS and myostatin immunoreactivity. Marked increases in the immunoreactivity of the oxidative stress marker, iNOS, which is a strong negative regulator of muscle growth, and myostatin, were detected in the gastrocnemius muscle bundles from DEXA control mice. However, EAP significantly and dose-dependently reduced these DEXA--induced increases in iNOS- and myostatin-immunoreactive muscle fibers. In addition, oxymetholone (50 mg/kg) significantly decreased the number of iNOS- and myostatin-positive muscle fibers compared with in the DEXA control mice. In particular, 400 mg/kg EAP exhibited favorable inhibitory activities on DEXA-induced increases in iNOS- and myostatin-immunoreactive fibers, which were comparable with the effects of oxymetholone (50 mg/kg). (A) Deionized distilled water-administered and saline-treated mice (intact vehicle control group). (B) Deionized distilled water-administered and DEXA-treated control mice (DEXA control group). (C) Oxymetholone (50 mg/kg)-administered and DEXA-treated reference mice (oxymetholone group). (D) EAP (400 mg/kg)-administered and DEXA-treated experimental mice (EAP400 group). (E) EAP (200 mg/kg)-administered and DEXA-treated experimental mice (EAP200 group). (F) EAP (100 mg/kg)-administered and DEXA-treated experimental mice (EAP100 group). Scale bars=40 *μ*m. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; iNOS, inducible nitric oxide synthase.](IJMM-41-03-1245-g09){#f10-ijmm-41-03-1245}

###### 

Oligonucleotides for quantitative polymerase chain reaction used in the present study.

  Target                            Sequences (5′-3′)          Size (bp)   Gene ID
  --------------------------------- -------------------------- ----------- ---------
  Atrogin-1                         F: CAGCTTCGTGAGCGACCTC     244         67731
  R: GGCAGTCGAGAAGTCCAGTC                                                  
  MuRF 1                            F: GACAGTCGCATTTCAAAGCA    194         433766
  R: GCCTAGCACTGACCTGGAAG                                                  
  PI3K p85α                         F: GCCAGTGGTCATTTGTGTTG    236         18708
  R: ACACAACCAGGGAAGTCCAG                                                  
  Akt1                              F: ATGAACGACGTAGCCATTGTG   116         11651
  R: TTGTAGCCAATAAAGGTGCCAT                                                
  Adenosine A1R                     F: TGTTCCCAGGGCCTTTCAC     155         11539
  R: TAATGGACTGAGACTAGCTTGACTGGTA                                          
  TRPV4                             F: CAGGACCTCTGGAAGAGTGC    165         63873
  R: AAGAGCTAGCCTGGACACCA                                                  
  Myostatin                         F: CCTCCACTCCGGGAACTGA     185         17700
  R: AAGAGCCATCACTGCTGTCATC                                                
  SIRT1                             F: TTCACATTGCATGTGTGTGG    175         93759
  R: TGAGGCCCAGTGCTCTAACT                                                  
  18S ribosomal RNA                 F: AGCCTGAGAAACGGCTACC     252         19791
  R: TCCCAAGATCCAACTACGAG                                                  

A1R, A1 receptor; Akt1, AKT serine/threonine kinase 1; F, forward; MuRF1, muscle RING-finger protein-1; PI3K, phosphatidylinositol 3-kinase; R, reverse; SIRT1, sirtuin 1; TRPV4, transient receptor potential cation cannel subfamily V member 4.

###### 

Primary antibodies and detection kits used in the present study.

  Antibodies or detection kits                                        Cat. no.   Source                                              Dilution
  ------------------------------------------------------------------- ---------- --------------------------------------------------- ----------
  Primary antibodies[a](#tfn2-ijmm-41-03-1245){ref-type="table-fn"}                                                                  
   Anti-cleaved caspase-3 (Asp175) polyclonal antibody                9661       Cell Signaling Technology Inc. (Danvers, MA, USA)   1:400
   Anti-cleaved PARP (Asp214) specific antibody                       9545       Cell Signaling Technology Inc.                      1:100
   Anti-4-hydroxynonenal polyclonal antibody                          Ab46545    Abcam (Cambridge, UK)                               1:100
   Anti-nitrotyrosine polyclonal antibody                             06-284     EMD Millipore (Billerica, CA, USA)                  1:200
   Anti-nitric oxide synthase 2 (N-20) polyclonal antibody            sc-651     Santa Cruz Biotechnology, Inc. (Dallas, TX, USA)    1:100
   Anti-GDF8/Myoststin antibody                                       Ab71808    Abcam                                               1:50
  Detection kits                                                                                                                     
   Vectastain Elite ABC kit                                           PK-6200    Vector Laboratories, Inc. (Burlingame, CA, USA)     1:50
   Peroxidase substrate kit                                           SK-4100    Vector Laboratories, Inc.                           1:50

All antibodies were diluted in 0.01 M phosphate-buffered saline in this experiment. ABC, avidin-biotin complex; GDF8, growth differentiation factor 8; PARP, poly (ADP-ribose) polymerase.

###### 

Alterations in body weight in mice with DEXA-induced muscle atrophy.

  Group           Weight gain (g)                                                                                                               
  --------------- ----------------- ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                      
   Intact         5.74±0.63         1.30±0.34                                                                                                   3.23±0.96
   DEXA           5.63±0.49         −5.50±0.81[a](#tfn4-ijmm-41-03-1245){ref-type="table-fn"}                                                   −4.00±0.63[b](#tfn5-ijmm-41-03-1245){ref-type="table-fn"}
  Reference                                                                                                                                     
   Oxymetholone   5.43±0.56         −1.19±0.47[a](#tfn4-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn6-ijmm-41-03-1245){ref-type="table-fn"}   0.20±0.66[b](#tfn5-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn7-ijmm-41-03-1245){ref-type="table-fn"}
  EAP-treated                                                                                                                                   
   400 mg/kg      5.68±0.58         −1.49±0.73[a](#tfn4-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn6-ijmm-41-03-1245){ref-type="table-fn"}   0.34±1.14[b](#tfn5-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn7-ijmm-41-03-1245){ref-type="table-fn"}
   200 mg/kg      5.71±0.41         −2.58±0.52[a](#tfn4-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn6-ijmm-41-03-1245){ref-type="table-fn"}   −0.73±0.55[b](#tfn5-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn7-ijmm-41-03-1245){ref-type="table-fn"}
   100 mg/kg      5.61±0.62         −3.24±0.95[a](#tfn4-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn6-ijmm-41-03-1245){ref-type="table-fn"}   −1.44±0.81[b](#tfn5-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn7-ijmm-41-03-1245){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by MW test.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the DEXA control group, as determined by MW test.

P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U.

###### 

Alterations in calf thickness in mice with DEXA-induced muscle atrophy.

  Group           Calf thickness alterations (mm)                                                                                                                
  --------------- --------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                       
   Intact         0.23±0.04                         0.09±0.06                                                                                                    0.32±0.06
   DEXA           0.23±0.04                         −0.91±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"}                                                    −0.68±0.05[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"}
  Reference                                                                                                                                                      
   Oxymetholone   0.27±0.05                         −0.34±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}   −0.07±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}
  EAP-treated                                                                                                                                                    
   400 mg/kg      0.24±0.05                         −0.33±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}   −0.09±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}
   200 mg/kg      0.25±0.03                         −0.52±0.10[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}   −0.27±0.09[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}
   100 mg/kg      0.24±0.03                         −0.62±0.04[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}   −0.39±0.05[a](#tfn9-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn10-ijmm-41-03-1245){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference.

###### 

Alterations in the serum biochemistry of mice with DEXA-induced muscle atrophy.

  Group           Serum levels (units)                                                                                                                                                                                                         
  --------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                     
   Intact         0.33±0.06                                                                                                    83.63±19.40                                                                                                     647.25±131.86
   DEXA           0.85±0.11[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"}                                                    274.13±51.85[b](#tfn13-ijmm-41-03-1245){ref-type="table-fn"}                                                    163.25±47.63[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                    
   Oxymetholone   0.45±0.05[c](#tfn14-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}   146.50±18.15[b](#tfn13-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn16-ijmm-41-03-1245){ref-type="table-fn"}   304.13±71.06[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}
  EAP-treated                                                                                                                                                                                                                                  
   400 mg/kg      0.49±0.09[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}   152.88±14.26[b](#tfn13-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn16-ijmm-41-03-1245){ref-type="table-fn"}   294.00±42.81[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}
   200 mg/kg      0.57±0.10[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}   176.63±15.40[b](#tfn13-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn16-ijmm-41-03-1245){ref-type="table-fn"}   264.25±53.73[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}
   100 mg/kg      0.66±0.13[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn15-ijmm-41-03-1245){ref-type="table-fn"}   210.75±29.35[b](#tfn13-ijmm-41-03-1245){ref-type="table-fn"},[f](#tfn17-ijmm-41-03-1245){ref-type="table-fn"}   242.50±29.24[a](#tfn12-ijmm-41-03-1245){ref-type="table-fn"},[g](#tfn18-ijmm-41-03-1245){ref-type="table-fn"}

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the intact control group, as determined by MW test.

P\<0.05 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the DEXA control group, as determined by LSD test.

P\<0.01 and

P\<0.05 compared with the DEXA control group, as determined by MW test.

P\<0.05 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U.

###### 

Alterations in the gastrocnemius muscle antioxidant defense system in mice with DEXA-induced muscle atrophy.

  Group           Activity levels (units)                                                                                                                                                                                                                                                                                                                                                                                                                                
  --------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Intact         1.84±0.76                                                                                                    22.12±10.46                                                                                                    0.64±0.15                                                                                                    34.14±10.58                                                                                                   7.08±2.11
   DEXA           8.32±1.11[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"}                                                    67.40±12.82[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"}                                                    0.16±0.07[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"}                                                    11.19±1.97[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"}                                                    1.84±0.24[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Oxymetholone   4.44±1.05[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   31.92±11.89[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}                                                    0.37±0.09[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   21.51±4.42[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}   3.64±0.70[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}
  EAP-treated                                                                                                                                                                                                                                                                                                                                                                                                                                                            
   400 mg/kg      4.48±1.20[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   31.89±10.67[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}                                                    0.38±0.10[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   20.81±4.57[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}   3.56±0.83[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}
   200 mg/kg      5.81±0.90[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   37.31±10.21[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn24-ijmm-41-03-1245){ref-type="table-fn"}   0.34±0.12[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   18.94±4.46[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}   3.12±0.49[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}
   100 mg/kg      6.42±0.76[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   45.19±12.22[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn22-ijmm-41-03-1245){ref-type="table-fn"}   0.29±0.08[a](#tfn20-ijmm-41-03-1245){ref-type="table-fn"},[f](#tfn25-ijmm-41-03-1245){ref-type="table-fn"}   17.52±2.30[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}   2.70±0.52[b](#tfn21-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn23-ijmm-41-03-1245){ref-type="table-fn"}

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the intact control group, as determined by MW test.

P\<0.01 compared with the DEXA control group, as determined by LSD test.

P\<0.01 compared with the DEXA control group, as determined by MW test.

P\<0.05 compared with the intact control group, as determined by LSD test.

P\<0.05 compared with the DEXA control group, as determined by LSD test. DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U.

###### 

Alterations in gastrocnemius muscle mRNA expression in mice with DEXA-induced muscle atrophy.

  Target      Groups                                                                                                                                                                                                                                                                                                                                                                                                          
  ----------- ----------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------
  Atrogin-1   0.99±0.07   4.90±0.67[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"}    2.20±0.44[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   2.29±0.44[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   3.24±0.66[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   3.81±0.51[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}
  MuRF 1      1.08±0.22   6.15±0.97[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"}    2.96±0.54[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   3.05±0.61[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   3.54±0.83[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   4.03±0.58[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}
  PI3K p85α   1.03±0.13   0.62±0.09[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"}    1.13±0.39[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}                                                    1.11±0.33[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}                                                    0.92±0.06[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn31-ijmm-41-03-1245){ref-type="table-fn"}   0.84±0.13[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn31-ijmm-41-03-1245){ref-type="table-fn"}
  Akt1        1.01±0.06   0.52±0.07[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"}    0.85±0.10[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.85±0.09[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.78±0.12[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.70±0.10[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}
  A1R         1.03±0.14   0.49±0.12[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"}    0.86±0.06[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.86±0.11[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.72±0.08[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.67±0.12[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}
  TRPV4       1.09±0.10   0.35±0.08[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"}    0.65±0.10[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.68±0.15[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.61±0.11[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}   0.52±0.13[c](#tfn29-ijmm-41-03-1245){ref-type="table-fn"},[d](#tfn30-ijmm-41-03-1245){ref-type="table-fn"}
  Myostatin   1.01±0.09   6.88±0.89[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"}    3.16±0.73[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   3.17±0.59[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   3.95±0.73[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   4.36±1.18[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}
  SIRT1       1.01±0.18   10.49±2.97[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"}   3.66±1.13[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   3.49±1.00[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   4.72±1.61[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}   5.28±1.15[a](#tfn27-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn28-ijmm-41-03-1245){ref-type="table-fn"}

Data are presented as the mean ± standard deviation of 8 mice. Expression levels were normalized to 18S ribosomal RNA expression. Oxymetholone was orally administered at 50 mg/kg levels, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by MW test.

P\<0.01 compared with the DEXA control group, as determined by MW test.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 compared with the DEXA control group, as determined by LSD test.

P\<0.05 compared with the intact control group, as determined by MW test. A1R, adenosine A1 receptor; Akt1, AKT serine/threonine kinase 1; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MuRF1, muscle RING-finger protein-1; MW, Mann Whitney U; PI3K, phosphatidylinositol 3-kinase; SIRT1, sirtuin 1; TRPV4, transient receptor potential cation cannel subfamily V member 4.

###### 

Alterations in gastrocnemius muscle histomorphometry in mice with DEXA-induced muscle atrophy.

  Variable                                Groups                                                                                                                                                                                                                                                                                                                                                                                                                   
  --------------------------------------- ------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  General histomorphometry                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Fiber diameter (*μ*m)                  51.36±10.37   23.35±5.26[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"}    38.03±6.72[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    37.39±7.30[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    34.77±6.65[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    31.87±4.30[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[c](#tfn35-ijmm-41-03-1245){ref-type="table-fn"}
   Collagen (%)                           4.09±1.71     31.96±4.71[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"}    16.72±3.30[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    15.93±4.62[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    19.36±3.02[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    23.57±5.64[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[f](#tfn38-ijmm-41-03-1245){ref-type="table-fn"}
  Immunohistomorphometry (fibers/mm^2^)                                                                                                                                                                                                                                                                                                                                                                                                                            
   Caspase-3                              2.13±2.53     41.13±10.45[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"}   20.88±5.03[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    19.00±2.83[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    23.63±5.26[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}    28.00±6.55[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}
  PARP                                    4.88±2.59     75.00±12.94[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"}   32.13±10.25[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   31.25±10.94[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   38.63±14.34[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   48.50±12.04[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}
   Nitrotyrosine                          5.63±2.67     67.75±12.37[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"}   34.63±13.09[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   31.38±14.51[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   38.25±15.18[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   46.00±13.31[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}
   4-HNE                                  3.75±1.91     75.38±11.67[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"}   42.25±10.50[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   40.38±10.14[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   45.75±10.98[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}   53.50±10.60[a](#tfn33-ijmm-41-03-1245){ref-type="table-fn"},[b](#tfn34-ijmm-41-03-1245){ref-type="table-fn"}
   iNOS                                   7.63±2.77     50.25±11.85[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"}   20.38±4.63[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    16.25±3.54[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    27.63±7.85[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    32.75±8.76[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}
   Myostatin                              1.13±0.83     51.88±11.15[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"}   21.75±4.83[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    20.38±5.40[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    32.75±4.98[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}    36.38±7.63[d](#tfn36-ijmm-41-03-1245){ref-type="table-fn"},[e](#tfn37-ijmm-41-03-1245){ref-type="table-fn"}

Data are presented as the mean ± standard deviation of 8 mice. Oxymetholone was orally administered at 50 mg/kg, dissolved in distilled water.

P\<0.01 compared with the intact control group, as determined by LSD test.

P\<0.01 and

P\<0.05 compared with the DEXA control group, as determined by LSD test.

P\<0.01 compared with the intact control group, as determined by MW test.

P\<0.01 and

P\<0.05 compared with the DEXA control group, as determined by MW test. 4-HNE, 4-hydroxynonenal; DEXA, dexamethasone; EAP, extracellular polysaccharides purified from *Aureobasidium pullulans* SM-2001; LSD, least-significant difference; MW, Mann Whitney U; iNOS, inducible nitric oxide synthase; PARP, cleaved poly (ADP-ribose) polymerase.

[^1]: Contributed equally
